Nuvectis Reports Positive Phase 1b NXP200 Study Data
Nuvectis reported durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas in its NXP200 Phase 1b study.
Nuvectis reported durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas in its NXP200 Phase 1b study.